Gyre Therapeutics (GYRE) Total Non-Current Liabilities (2014 - 2026)

Gyre Therapeutics (GYRE) has reported Total Non-Current Liabilities for 10 consecutive years, with $22.2 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Total Non-Current Liabilities changed 0.38% year-over-year to $22.2 million; the TTM figure through Mar 2026 stood at $22.2 million (changed 0.38% YoY), while the FY2025 annual figure was $22.4 million, up 5.0% from the prior year.
• Total Non-Current Liabilities retreated to $22.2 million in Q1 2026 per GYRE's latest filing, from $22.4 million in the prior quarter.
• Across five years, Total Non-Current Liabilities topped out at $38.0 million in Q4 2023 and bottomed at $1.8 million in Q3 2023.
• Historically, Total Non-Current Liabilities has averaged $18.6 million across 5 years, with a median of $20.7 million in 2024.
• On a YoY basis, Total Non-Current Liabilities climbed as much as 1699.95% in 2024 and fell as far as 43.88% in 2024.
• Gyre Therapeutics' Total Non-Current Liabilities stood at $12.5 million in 2022, then jumped by 203.25% to $38.0 million in 2023, then tumbled by 43.88% to $21.3 million in 2024, then advanced by 5.0% to $22.4 million in 2025, then decreased by 1.09% to $22.2 million in 2026.
• Business Quant data shows GYRE's Total Non-Current Liabilities at $22.2 million in Q1 2026, $22.4 million in Q4 2025, and $18.7 million in Q3 2025.